WITHUS PHARMACEUTICALLTD Past Earnings Performance
Past criteria checks 3/6
WITHUS PHARMACEUTICALLTD's earnings have been declining at an average annual rate of -23.2%, while the Pharmaceuticals industry saw earnings growing at 10.4% annually. Revenues have been growing at an average rate of 10.9% per year. WITHUS PHARMACEUTICALLTD's return on equity is 8.8%, and it has net margins of 9.9%.
Key information
-23.2%
Earnings growth rate
-45.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 11.3% |
| Revenue growth rate | 10.9% |
| Return on equity | 8.8% |
| Net Margin | 9.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Here's What Withuspharmaceutical Co.,Ltd.'s (KOSDAQ:330350) Shareholder Ownership Structure Looks Like
Feb 17
Calculating The Intrinsic Value Of Withuspharmaceutical Co.,Ltd. (KOSDAQ:330350)
Jan 13
We're Not Counting On WithuspharmaceuticalLtd (KOSDAQ:330350) To Sustain Its Statutory Profitability
Dec 09Revenue & Expenses BreakdownBeta
How WITHUS PHARMACEUTICALLTD makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 80,119 | 7,959 | 37,347 | 1,868 |
| 30 Sep 23 | 68,975 | 3,264 | 34,399 | 2,067 |
| 30 Jun 23 | 65,794 | 1,606 | 32,112 | 2,410 |
| 31 Mar 23 | 63,032 | 1,057 | 30,742 | 2,615 |
| 31 Dec 22 | 64,680 | 2,479 | 29,849 | 2,357 |
| 30 Sep 22 | 64,618 | 5,424 | 27,797 | 2,108 |
| 30 Jun 22 | 62,461 | 5,282 | 27,136 | 1,852 |
| 31 Mar 22 | 61,564 | 5,089 | 26,754 | 1,586 |
| 31 Dec 21 | 57,419 | 4,264 | 26,328 | 1,420 |
| 31 Dec 20 | 53,406 | 6,652 | 22,807 | 1,807 |
| 30 Sep 20 | 52,842 | 7,075 | 22,229 | 1,983 |
| 30 Jun 20 | 52,393 | 8,039 | 21,150 | 1,512 |
Quality Earnings: A330350 has a high level of non-cash earnings.
Growing Profit Margin: A330350's current net profit margins (9.9%) are higher than last year (3.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A330350's earnings have declined by 23.2% per year over the past 5 years.
Accelerating Growth: A330350's earnings growth over the past year (221%) exceeds its 5-year average (-23.2% per year).
Earnings vs Industry: A330350 earnings growth over the past year (221%) exceeded the Pharmaceuticals industry 34.6%.
Return on Equity
High ROE: A330350's Return on Equity (8.8%) is considered low.